Discover results-proven tools and methodologies for your clinical development. Learn how to improve your trial design, data collection and clinical supply. In addition, get key information on how to improve your patient recruitment and retention. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in clinical development to exchange ideas on best practice and share case studies on innovation within the area.
At the start of 2016, the industry predicted many market access trends. As we come to the end of the year, let us look at the market access trends predicted at the start of 2016. How have these predictions unfolded so far and what will be the next set of trends for the coming year? Full Article »
Ahead of the Clinical Trial Supply Europe event, Pharma IQ presents interviews filmed live at last year's CTS event. In this interview Michael Pompey talks about the daily challenges he faces as a clinical trial supply manager at Sandoz and he discusses his experience with IRT. Full Video »
For Dr Hella Kohlhof, the study of epigenetics was not love at first sight, however the potential it posesses eventually won her over. Now Dr Kohlhof is Manager of Translational Pharmacology at 4SC AG and is applying epigenetic knowledge in a phase 1 first-in-man trial. She talks to us about what role epigentics plays in cancer and how new Full Podcast »
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells, leading to major side effects such as loss of hair, nausea and vomiting, and risk of infection. Survival was sometimes better, but not much better, depending on the type of cancer and the patient's own genetic and physiological make-up. The big advantage of IO therapies is that they can target specific receptors on the cancer cells and destroy them while leaving the healthy cells alone. This will also help reduce some of the traditional side effects when healthy cells are destroyed. Full Column »
Pharma IQ speaks to Dr Samantha Carmichael, Lead Pharmacist Clinical Trials of NHS Greater Glasgow & Clyde and Mandy Wan, Lead Paediatric Research Pharmacist, Evelina London Children’s Hospital in regards to the growing culture of site centricity in today’s clinical trials. Full Whitepaper »